查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016937

尿液檢查市場：依產品、應用和最終用途分類－2026-2032年全球市場預測

Urinalysis Market by Product, Application, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年尿液檢查市場價值 42.6 億美元，預計到 2026 年將成長至 45.4 億美元，複合年成長率為 6.85%，到 2032 年將達到 67.8 億美元。

主要市場統計數據
基準年 2025 42.6億美元
預計年份：2026年 45.4億美元
預測年份 2032 67.8億美元
複合年成長率 (%) 6.85%

詳細介紹診斷技術創新、臨床重點和數據整合如何重新定義尿液檢查在所有醫療保健環境中的作用。

尿液檢查仍是基層醫療、醫院檢查室和分散式檢查環境中至關重要的診斷工具，既可作為快速篩檢方法，也可作為臨床醫生進行長期監測的手段。在自動化、數位影像處理、試劑化學和互通性等創新技術的推動下，該領域正在超越其傳統角色。這些進步有望提高診斷準確性，同時縮短結果獲取時間。因此，檢測途徑也從社區醫療機構使用的照護現場試紙，到整合到高通量檢查室工作流程中的全自動分析儀，涵蓋了廣泛的臨床應用場景。

自動化、數位分析、分散式檢查和供應鏈彈性的整合如何重新定義診斷工作流程和病患照護路徑。

近年來，尿液檢查的實施方式、結果解讀方式以及與診療流程的整合方式都發生了變革性變化。自動化技術超越了簡單的機械化，融合了先進的影像分析和模式識別技術，使檢查室能夠以更高的一致性處理更多檢體。同時，軟體主導的解決方案透過標記異常結果和減少人工核查的工作量來最佳化解讀流程，從而提高檢查室的處理能力並增強報告的一致性。

評估 2025 年價格調整如何重塑耗材和診斷設備的採購趨勢、籌資策略和成本結構。

2025年關稅措施的實施對尿液檢查供應鏈產生了多方面的影響，耗材和設備都發生了顯著變化。依賴進口的企業面臨試劑、試紙、一次性用品和某些設備零件進口成本的增加，這導致籌資策略和定價模式受到更嚴格的審查。因此，檢查室和醫療機構正在重新評估其整體擁有成本（TCO），不僅包括初始資本投資，還包括持續的耗材成本和服務合約。

細分市場分析揭示了產品、臨床應用和最終用途的差異如何影響採購行為、設計重點和臨床效用。

對市場細分的詳細分析揭示了不同產品、應用和最終用途類別在技術和採用趨勢上的差異，這些差異影響著商業性和臨床的優先事項。按產品分類，市場分為耗材和儀器。在耗材方面，試紙條、一次性產品和試劑類別的性能和價值提案各不相同，易用性、儲存穩定性和批間一致性是影響買家偏好的主要因素。相比之下，儀器則以其自動化程度和分析方法為特徵。全自動尿沉渣分析儀和生化尿液分析儀兼具處理能力和標準化功能。前者進一步細分為流式細胞技術和顯微鏡尿液分析儀，後者則細分為全自動生化尿沉渣分析儀和半全自動尿沉渣分析儀。每種分析儀在靈敏度、運行時間和安裝空間方面各有側重。

本報告說明了各地區的診斷環境，重點介紹了美洲、歐洲、中東和非洲以及亞太地區的實施模式、監管環境和商業性機會。

區域趨勢正在影響戰略重點，美洲、歐洲、中東和非洲以及亞太地區的部署模式和法規環境差異顯著。在美洲，成熟的檢查室網路和對價值醫療日益成長的重視推動了對自動化系統的需求，這些系統能夠提升處理能力並實現標準化報告。同時，市場參與企業也在探索照護現場(PoC) 解決方案，以擴大其篩檢範圍。在歐洲、中東和非洲，不同的監管環境和異質的醫療基礎設施要求解決方案具有高度的適應性，能夠在集中式和分散式環境中運行，互通性和符合區域標準至關重要。

我們分析公司的策略性舉措，揭示產品系列、服務模式和數位夥伴關係關係如何塑造其在診斷領域的競爭優勢。

產業相關人員正透過差異化策略來應對不斷變化的臨床和商業性壓力，這些策略著重於產品廣度、服務豐富度和數位轉型。領先的製造商正在擴展其耗材產品組合以確保持續的收入，同時提升儀器的易用性和自動化程度，從而減輕檢查室的整體營運負擔。一些公司優先考慮將分析儀器、試劑和服務合約結合的整合解決方案，以確保生命週期價值，並在分散的站點提供可預測的性能。

制定切實可行的策略挑戰，以加強供應鏈韌性，加速自動化應用，並透過整合服務模式擴大經常性收入。

產業領導企業應優先採取一系列切實可行的措施，以最大限度地滿足臨床需求並降低營運風險。首先，他們應實現供應鏈多元化，並促進本地化生產和組裝，以減少貿易中斷的影響並縮短交貨時間。同時，應在合約條款中加入可靠性獎勵和情境規劃，為關鍵耗材預留庫存緩衝。其次，他們應加快對自動化和人工智慧 (AI) 技術的投資，以減少人工審核並提高診斷一致性，從而確保檢查室效率的顯著提升和臨床醫生的信心。

採用嚴謹的混合方法研究途徑，結合專家訪談、第二手資料和檢驗協議，確保研究結果的可靠性和透明度。

本分析採用混合研究方法，將質性專家見解與系統收集的二手資訊和結構化資料檢驗結合。主要資訊來源包括對實驗室負責人、臨床病理學家、採購專家和產品開發經理的訪談，旨在了解第一線觀點對營運限制、臨床優先事項和採購行為的看法。次要資訊來源包括同行評審文獻、監管文件、技術白皮書和公開的企業披露信息，旨在提供有關技術趨勢和產品特性的背景信息。

簡明扼要地總結了決定尿液檢查分析診斷領域競爭地位的技術、營運和商業性要求。

簡而言之，尿液檢查目前正處於轉折點，技術創新、臨床重點的轉變以及採購環境的變化交織在一起，帶來了新的營運和商業挑戰。自動化和數位化解讀提高了檢測的準確性和處理能力，而分散化和家庭檢測的普及則擴大了依賴尿液檢查診斷的臨床實踐範圍。為了因應這些趨勢，相關人員需要重新思考產品設計、供應鏈結構和服務模式，以持續滿足臨床醫生的需求和病患的期望。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：尿液檢查市場：依產品分類

  • 消耗品
    • 油尺
    • 一次性產品
    • 試劑
  • 裝置
    • 自動尿沉渣分析儀
      • 流式細胞技術尿液分析儀
      • 尿液顯微鏡分析儀
    • 尿液生化分析儀
      • 自動生化分析儀
      • 半自動尿沉渣分析儀

第9章：尿液檢查市場：依應用領域分類

  • 糖尿病
  • 高血壓
  • 腎臟疾病
  • 肝病
  • 尿道感染（UTI）篩檢

第10章：尿液檢查市場：依最終用途分類

  • 臨床檢查室
  • 居家照護
  • 醫院
  • 研究和學術機構

第11章尿液檢查市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章尿液檢查市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章尿液檢查市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國尿液檢查市場

第15章：中國尿液檢查市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Accurex Biomedical Pvt. Ltd.
  • ACON Laboratories, Inc.
  • Analyticon Biotechnogies GmBH
  • ARKRAY Inc.
  • Beckman Coulter, Inc.
  • BIOBASE Group
  • Cardinal Health, Inc.
  • Clarity Diagnostics, LLC
  • Danaher Corporation
  • DIALAB GmbH
  • Dirui Industrial Co. Ltd.
  • Erba Mannheim
  • F. Hoffmann-La Roche Ltd
  • Genuine Biosystem Pvt Ltd.
  • High Technology, Inc.
  • PZ Cormay SA
  • QuidelOrtho Corporation
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Sysmex Asia Pacific Pte Ltd.
  • Teco Diagnostics
  • Thermo Fisher Scientific Inc.
  • YD Diagnostics
Product Code: MRR-034B5003034D

The Urinalysis Market was valued at USD 4.26 billion in 2025 and is projected to grow to USD 4.54 billion in 2026, with a CAGR of 6.85%, reaching USD 6.78 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 4.26 billion
Estimated Year [2026] USD 4.54 billion
Forecast Year [2032] USD 6.78 billion
CAGR (%) 6.85%

An informed introduction to how diagnostic innovations, clinical priorities, and data connectivity are redefining the role of urinalysis across care settings

Urinalysis remains a cornerstone diagnostic tool across primary care, hospital laboratories, and decentralized testing environments, serving clinicians as both a rapid screening mechanism and a longitudinal monitoring instrument. The discipline is evolving beyond its traditional role, propelled by innovations in automation, digital imaging, reagent chemistry, and interoperability that promise to tighten diagnostic accuracy while reducing time-to-result. Consequently, testing pathways now span from point-of-care strips used in community settings to fully automated analyzers integrated into high-throughput laboratory workflows, reflecting a broad continuum of clinical use cases.

In parallel, clinical priorities are shifting toward earlier detection and continuous monitoring of chronic conditions such as diabetes and kidney disease, which places greater emphasis on reliable urine-based biomarkers and standardized reporting. As stakeholders adapt, the interplay between technological maturation, regulatory expectations, and shifting care models is reshaping procurement and service models. Therefore, a strategic view of the landscape must consider not only device capabilities and consumable logistics but also data flows, quality assurance practices, and the emergent demand for patient-centric and remote testing modalities.

How convergence of automation, digital interpretation, decentralized testing, and supply chain resilience is redefining diagnostic workflows and patient pathways

Recent years have brought transformative shifts that are redefining how urinalysis is conducted, interpreted, and integrated into care pathways. Automation technologies are moving beyond mechanization to include advanced image analysis and pattern recognition, enabling laboratories to process higher volumes with improved consistency. Simultaneously, software-driven solutions are enhancing interpretive workflows by flagging anomalous results and reducing manual review burden, which contributes to improved laboratory throughput and more consistent reporting.

Concurrently, there is heightened emphasis on decentralization and patient empowerment. Home-based testing platforms and simplified point-of-care systems are becoming more prevalent, chiefly to support chronic disease management and community screening programs. These platforms are increasingly designed to interoperate with electronic health records and telehealth systems, supporting seamless clinician oversight. Moreover, supply chain resiliency and sustainability considerations are influencing procurement strategies, while regulatory frameworks continue to evolve to accommodate new technologies and ensure reliable performance across diverse settings. Taken together, these shifts are enabling faster clinical decision-making and creating opportunities for novel service models and recurring revenue streams tied to consumables and digital services.

Assessment of how 2025 tariff shifts have reshaped procurement dynamics, sourcing strategies, and cost structures across consumables and diagnostic instruments

The introduction of tariff measures in 2025 has exerted a multifaceted influence on the urinalysis supply chain, touching both consumables and instruments in meaningful ways. Import-dependent operators have experienced elevated landed costs for reagents, dipsticks, disposables, and certain instrument components, which has intensified scrutiny of procurement strategies and pricing models. As a result, laboratories and healthcare providers are reassessing total cost of ownership considerations, factoring in not only initial capital outlays but also recurring consumable expenses and service commitments.

In response to these pressures, manufacturers and distributors have accelerated diversification of their sourcing footprints, pursued local manufacturing partnerships, and explored regional assembly to mitigate exposure to tariff-related volatility. These adjustments are producing longer-term shifts in supplier relationships and inventory policies, as entities emphasize dual sourcing, strategic inventory buffers, and contractual protections. In addition, some stakeholders have prioritized product modularity and design-for-manufacture approaches to reduce reliance on tariff-impacted components. Collectively, these adaptations are reshaping procurement cycles and commercial negotiations while influencing product roadmaps and pricing strategies across the ecosystem.

Segment-level analysis revealing how product, clinical application, and end-use distinctions influence procurement behavior, design priorities, and clinical utility

A granular examination of segmentation reveals differentiated technology and adoption dynamics across product, application, and end-use categories that shape commercial and clinical priorities. Based on Product, the landscape separates into Consumables and Instruments; within Consumables, distinct performance and value propositions emerge across dipsticks, disposables, and reagents where ease of use, shelf stability, and batch-to-batch consistency are primary drivers of buyer preference. In contrast, Instruments are distinguished by their automation level and analytical approach: Automated Urine Sediment Analyzers and Biochemical Urine Analyzers deliver throughput and standardization with the former further bifurcated into flowcytometric urine analyzers and microscopic urine analyzers and the latter into automated biochemical analyzers and semi-automated urine sediment analyzers, each offering a different balance of sensitivity, hands-on time, and laboratory footprint.

Based on Application, testing is organized around clinical priorities such as diabetes, hypertension, kidney disease, liver disease, and UTI screening, with each indication imposing unique requirements for sensitivity, quantitative reporting, and longitudinal comparability. For instance, chronic disease monitoring demands robust reproducibility and integration with longitudinal electronic records, whereas UTI screening emphasizes rapid turnaround and high negative predictive value. Based on End Use, distinct buyer archetypes-clinical laboratories, home care settings, hospitals, and research & academics-exhibit divergent procurement behavior, service expectations, and technical requirements, which in turn inform product design, service models, and commercialization strategies.

Regional diagnostic landscapes explained to highlight adoption patterns, regulatory variation, and commercial opportunities across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics are informing strategic priorities, with adoption patterns and regulatory environments varying considerably across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established laboratory networks and a growing emphasis on value-based care are driving demand for automated systems that enable throughput and standardized reporting, while market participants are also exploring point-of-care solutions to expand screening initiatives. In Europe, Middle East & Africa, diverse regulatory landscapes and heterogeneous healthcare infrastructures require adaptable solutions that can operate across centralized and decentralized settings, with an emphasis on interoperability and compliance with regional standards.

Asia-Pacific presents both rapid adoption curves and localized manufacturing strengths, where large population health initiatives and rising investment in diagnostics are accelerating uptake of both automated analyzers and decentralized testing platforms. Meanwhile, countries in the region vary in reimbursement approaches and laboratory capacity, creating opportunities for scalable, cost-efficient solutions. Across regions, supply chain considerations, local regulatory approvals, and strategic partnerships with regional distributors remain critical for successful market entry and sustained growth.

Corporate strategic moves examined to reveal how product portfolios, service models, and digital partnerships are shaping competitive advantage in diagnostics

Industry participants are responding to evolving clinical and commercial pressures through differentiated strategies focused on product breadth, service intensity, and digital enablement. Leading manufacturers are expanding consumable portfolios to capture recurring revenue while concurrently enhancing instrument usability and automation to reduce total operational burden on laboratories. Some firms are prioritizing integrated solutions that combine analyzers, reagents, and service contracts to lock in lifecycle value and to provide predictable performance across decentralized sites.

Additionally, there is a notable trend toward partnering with digital platform providers to enable remote monitoring, predictive maintenance, and streamlined data exchange with electronic medical records. These alliances enhance customer retention and provide new monetizable service layers. Competitive dynamics also favor organizations that invest in regulatory readiness and quality systems, enabling faster approvals in multiple jurisdictions. Finally, nimble entrants often focus on niche segments-such as home testing or specialized sediment analysis-leveraging agility to secure footholds and to commercialize rapidly while larger players pursue scale and integration.

Actionable strategic imperatives to strengthen supply resilience, accelerate automation adoption, and expand recurring revenue through integrated service models

Industry leaders should prioritize a set of pragmatic actions to capitalize on clinical demand and to mitigate operational risk. First, diversify supply chains and pursue regional manufacturing or assembly to reduce exposure to trade disruptions and to shorten delivery lead times. This step should be accompanied by contractual terms that incentivize reliability and by scenario planning that incorporates inventory buffers for critical consumables. Second, accelerate investment in automation and artificial intelligence capabilities that reduce manual review and improve diagnostic consistency, thereby delivering measurable laboratory efficiencies and clinician confidence.

Third, expand offerings for decentralized testing and home care to capture shifting care models, integrating device outputs with clinical workflows and health record systems to ensure clinician oversight and continuity of care. Fourth, design commercial models that balance instrument sales with consumable and service revenue streams to create recurring income and stronger customer relationships. Finally, engage proactively with regulators and payers to demonstrate clinical utility and cost-effectiveness, and to align product development with reimbursement and quality expectations. Implementing these recommendations in a coordinated manner will strengthen resilience and create sustainable differentiation across competitive markets.

Rigorous mixed-methods research approach combining expert interviews, secondary evidence, and validation protocols to ensure robust and transparent findings

The underlying analysis draws on a mixed-methods research approach that triangulates qualitative insights from subject-matter experts with systematically collected secondary information and structured data validation. Primary inputs include interviews with laboratory directors, clinical pathologists, procurement specialists, and product development leaders to capture first-hand perspectives on operational constraints, clinical priorities, and purchasing behavior. Secondary inputs encompass peer-reviewed literature, regulatory documentation, technical white papers, and publicly available company disclosures to contextualize technology trends and product features.

Findings were validated through cross-checking against multiple independent sources and by reconciling divergent viewpoints via expert panels. Segmentation frameworks were applied to ensure consistent classification across product, application, and end-use categories, and sensitivity checks were performed to gauge the robustness of thematic conclusions. Limitations include the variable availability of granular operational metrics across regions and potential biases inherent in stakeholder interviews; these were mitigated through careful respondent selection and methodological transparency. Ethical considerations guided primary research, with informed consent and confidentiality protections for interview participants.

Concise conclusion synthesizing technological, operational, and commercial imperatives that will determine competitive positioning in urinalysis diagnostics

In sum, urinalysis is at an inflection point where technological innovation, evolving clinical priorities, and shifting procurement realities are converging to create new operational and commercial imperatives. Automation and digital interpretation are enhancing accuracy and throughput, while decentralization and home-based testing are broadening the points of care that rely on urine-based diagnostics. These developments demand that stakeholders rethink product design, supply chain architecture, and service models to remain responsive to clinician needs and to patient expectations.

Strategic investments in supply chain diversification, automation, integrated consumable services, and regulatory engagement will be essential to capture emerging opportunities and to protect margins amid cost pressures. By aligning product roadmaps with clinical workflows and by leveraging digital capabilities for data integration and remote support, organizations can both improve clinical outcomes and create sustainable competitive differentiation. The overarching conclusion is that timely, coordinated actions across technology, operations, and commercial functions will determine which organizations lead the next phase of advancement in urinalysis diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Urinalysis Market, by Product

  • 8.1. Consumables
    • 8.1.1. Dipsticks
    • 8.1.2. Disposables
    • 8.1.3. Reagents
  • 8.2. Instruments
    • 8.2.1. Automated Urine Sediment Analyzers
      • 8.2.1.1. Flowcytometric Urine Analyzers
      • 8.2.1.2. Microscopic Urine Analyzers
    • 8.2.2. Biochemical Urine Analyzer
      • 8.2.2.1. Automated Biochemical Analyzers
      • 8.2.2.2. Semi-automated Urine Sediment Analyzers

9. Urinalysis Market, by Application

  • 9.1. Diabetes
  • 9.2. Hypertension
  • 9.3. Kidney Disease
  • 9.4. Liver Disease
  • 9.5. UTI Screening

10. Urinalysis Market, by End Use

  • 10.1. Clinical Laboratories
  • 10.2. Home Care
  • 10.3. Hospitals
  • 10.4. Research & Academics

11. Urinalysis Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Urinalysis Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Urinalysis Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Urinalysis Market

15. China Urinalysis Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. Accurex Biomedical Pvt. Ltd.
  • 16.7. ACON Laboratories, Inc.
  • 16.8. Analyticon Biotechnogies GmBH
  • 16.9. ARKRAY Inc.
  • 16.10. Beckman Coulter, Inc.
  • 16.11. BIOBASE Group
  • 16.12. Cardinal Health, Inc.
  • 16.13. Clarity Diagnostics, LLC
  • 16.14. Danaher Corporation
  • 16.15. DIALAB GmbH
  • 16.16. Dirui Industrial Co. Ltd.
  • 16.17. Erba Mannheim
  • 16.18. F. Hoffmann-La Roche Ltd
  • 16.19. Genuine Biosystem Pvt Ltd.
  • 16.20. High Technology, Inc.
  • 16.21. PZ Cormay S.A.
  • 16.22. QuidelOrtho Corporation
  • 16.23. Randox Laboratories Ltd.
  • 16.24. Siemens Healthineers AG
  • 16.25. Sysmex Asia Pacific Pte Ltd.
  • 16.26. Teco Diagnostics
  • 16.27. Thermo Fisher Scientific Inc.
  • 16.28. YD Diagnostics

LIST OF FIGURES

  • FIGURE 1. GLOBAL URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL URINALYSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL URINALYSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL URINALYSIS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL URINALYSIS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL URINALYSIS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL URINALYSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL URINALYSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL URINALYSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL URINALYSIS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL URINALYSIS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL URINALYSIS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL URINALYSIS MARKET SIZE, BY DIPSTICKS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL URINALYSIS MARKET SIZE, BY DIPSTICKS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL URINALYSIS MARKET SIZE, BY DIPSTICKS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL URINALYSIS MARKET SIZE, BY DISPOSABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL URINALYSIS MARKET SIZE, BY DISPOSABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL URINALYSIS MARKET SIZE, BY DISPOSABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL URINALYSIS MARKET SIZE, BY REAGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL URINALYSIS MARKET SIZE, BY REAGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL URINALYSIS MARKET SIZE, BY REAGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL URINALYSIS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL URINALYSIS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL URINALYSIS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL URINALYSIS MARKET SIZE, BY FLOWCYTOMETRIC URINE ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL URINALYSIS MARKET SIZE, BY FLOWCYTOMETRIC URINE ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL URINALYSIS MARKET SIZE, BY FLOWCYTOMETRIC URINE ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL URINALYSIS MARKET SIZE, BY MICROSCOPIC URINE ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL URINALYSIS MARKET SIZE, BY MICROSCOPIC URINE ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL URINALYSIS MARKET SIZE, BY MICROSCOPIC URINE ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL URINALYSIS MARKET SIZE, BY AUTOMATED BIOCHEMICAL ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL URINALYSIS MARKET SIZE, BY SEMI-AUTOMATED URINE SEDIMENT ANALYZERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL URINALYSIS MARKET SIZE, BY SEMI-AUTOMATED URINE SEDIMENT ANALYZERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL URINALYSIS MARKET SIZE, BY SEMI-AUTOMATED URINE SEDIMENT ANALYZERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL URINALYSIS MARKET SIZE, BY DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL URINALYSIS MARKET SIZE, BY DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL URINALYSIS MARKET SIZE, BY DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL URINALYSIS MARKET SIZE, BY HYPERTENSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL URINALYSIS MARKET SIZE, BY HYPERTENSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL URINALYSIS MARKET SIZE, BY HYPERTENSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL URINALYSIS MARKET SIZE, BY KIDNEY DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL URINALYSIS MARKET SIZE, BY KIDNEY DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL URINALYSIS MARKET SIZE, BY KIDNEY DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL URINALYSIS MARKET SIZE, BY LIVER DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL URINALYSIS MARKET SIZE, BY LIVER DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL URINALYSIS MARKET SIZE, BY LIVER DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL URINALYSIS MARKET SIZE, BY UTI SCREENING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL URINALYSIS MARKET SIZE, BY UTI SCREENING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL URINALYSIS MARKET SIZE, BY UTI SCREENING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL URINALYSIS MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL URINALYSIS MARKET SIZE, BY CLINICAL LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL URINALYSIS MARKET SIZE, BY CLINICAL LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL URINALYSIS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL URINALYSIS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL URINALYSIS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL URINALYSIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL URINALYSIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL URINALYSIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL URINALYSIS MARKET SIZE, BY RESEARCH & ACADEMICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL URINALYSIS MARKET SIZE, BY RESEARCH & ACADEMICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL URINALYSIS MARKET SIZE, BY RESEARCH & ACADEMICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL URINALYSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS URINALYSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL URINALYSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. GCC URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 145. GCC URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 146. GCC URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 148. GCC URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 149. GCC URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. GCC URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. G7 URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 169. G7 URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 170. G7 URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 172. G7 URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 173. G7 URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 174. G7 URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. NATO URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 177. NATO URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 178. NATO URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 180. NATO URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 181. NATO URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. NATO URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL URINALYSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA URINALYSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA URINALYSIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA URINALYSIS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA URINALYSIS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA URINALYSIS MARKET SIZE, BY AUTOMATED URINE SEDIMENT ANALYZERS, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA URINALYSIS MARKET SIZE, BY BIOCHEMICAL URINE ANALYZER, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA URINALYSIS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA URINALYSIS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)